A link between interferon and augmented plasmin generation in exocrine gland damage in Sjögren's syndrome

Journal of Autoimmunity

Volumn 40, Issue 1, 2013, Pages 122-133

  Gliozzi, Maria ^a   Greenwell Wild, Teresa ^a   Jin, Wenwen ^a   Moutsopoulos, Niki M ^a   Kapsogeorgou, Efstathia ^b   Moutsopoulos, Haralampos M ^b   Wahl, Sharon M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cytokine; Macrophage; MMP; Plasminogen; Salivary gland; TPA

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 17; JANUS KINASE; MACROPHAGE ELASTASE; MATRILYSIN; PLASMIN; STAT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BONE MARROW CELL; CELLS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; LACRIMAL GLAND; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND BIOPSY; SALIVARY GLAND DISEASE; SJOEGREN SYNDROME; TH1 CELL; TH17 CELL; TISSUE INJURY; WESTERN BLOTTING;

EXOCRINE GLANDS; FIBRINOLYSIN; HUMANS; INFLAMMATION; INTERFERON-ALPHA; INTERFERON-GAMMA; JANUS KINASES; LYMPHOCYTE ACTIVATION; MACROPHAGES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PLASMINOGEN; PLASMINOGEN ACTIVATORS; SALIVARY GLANDS; SJOGREN'S SYNDROME; STAT TRANSCRIPTION FACTORS; TH1 CELLS; TH17 CELLS;

EID: 84873718117     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.09.003     Document Type: Article

References (69)

1. Voulgarelis M., Dafni U.G., Isenberg D.A., Moutsopoulos H.M. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 1999, 42:1765-1772.
2. Ice J.A., Li H., Adrianto I., Lin P.C., Kelly J.A., Montgomery C.G., et al. Genetics of Sjögren's syndrome in the genome-wide association era. J Autoimmun 2012, 39:57-63.
3. Katsifis G.E., Moutsopoulos N.M., Wahl S.M. T lymphocytes in Sjogren's syndrome: contributors to and regulators of pathophysiology. Clin Rev Allergy Immunol 2007, 32:252-264.
4. Manoussakis M.N., Boiu S., Korkolopoulou P., Kapsogeorgou E.K., Kavantzas N., Ziakas P., et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007, 56:3977-3988.
5. Greenwell-Wild T., Moutsopoulos N.M., Gliozzi M., Kapsogeorgou E., Rangel Z., Munson P.J., et al. Chitinases in the salivary glands and circulation of patients with Sjogren's syndrome: macrophage harbingers of disease severity. Arthritis Rheum 2011, 63:3103-3115.
6. Katsifis G.E., Rekka S., Moutsopoulos N.M., Pillemer S., Wahl S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009, 175:1167-1177.
7. Deiteren K., Hendriks D., Scharpe S., Lambeir A.M., Carboxypeptidase M. Multiple alliances and unknown partners. Clin Chim Acta 2009, 399:24-39.
8. Conus S., Simon H.U. Cathepsins and their involvement in immune responses. Swiss Med Wkly 2010, 140:w13042.
9. Duffy M.J. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004, 10:39-49.
10. Sharma M.C., Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 2007, 13:3568-3575.
11. Brownstein C., Deora A.B., Jacovina A.T., Weintraub R., Gertler M., Khan K.M., et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 2004, 103:317-324.
12. Shi Z., Stack M.S. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem J 2007, 407:153-159.
13. O'Connell P.A., Surette A.P., Liwski R.S., Svenningsson P., Waisman D.M. S100A10 regulates plasminogen-dependent macrophage invasion. Blood 2010, 116:1136-1146.
14. Wen J., Nikitakis N.G., Chaisuparat R., Greenwell-Wild T., Gliozzi M., Jin W., et al. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am J Pathol 2011, 178:2866-2878.
15. Zhang Y., DeWitt D.L., McNeely T.B., Wahl S.M., Wahl L.M. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997, 99:894-900.
16. Taggart C.C., Cryan S.A., Weldon S., Gibbons A., Greene C.M., Kelly E., et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005, 202:1659-1668.
17. Ma G., Greenwell-Wild T., Lei K., Jin W., Swisher J., Hardegen N., et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004, 200:1337-1346.
18. Ashcroft G.S., Lei K., Jin W., Longenecker G., Kulkarni A.B., Greenwell-Wild T., et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 2000, 6:1147-1153.
19. Zhu J., Nathan C., Jin W., Sim D., Ashcroft G.S., Wahl S.M., et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002, 111:867-878.
20. Angelov N., Moutsopoulos N., Jeong M.J., Nares S., Ashcroft G., Wahl S.M. Aberrant mucosal wound repair in the absence of secretory leukocyte protease inhibitor. Thromb Haemost 2004, 92:288-297.
21. Virtanen O.J., Siren V., Multanen J., Farkkila M., Leivo I., Vaheri A., et al. Plasminogen activators and their inhibitors in human saliva and salivary gland tissue. Eur J Oral Sci 2006, 114:22-26.
22. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
23. Daniels T.E., Whitcher J.P. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjogren's syndrome. Arthritis Rheum 1994, 37:869-877.
24. Tarpley T.M., Anderson L.G., White C.L. Minor salivary gland involvement in Sjogren's syndrome. Oral Surg Oral Med Oral Pathol 1974, 37:64-74.
25. Zeher M., Szegedi G., Csiki Z., Cseh A., Adany R. Fibrinolysis-resistant fibrin deposits in minor labial salivary glands of patients with Sjogren's syndrome. Clin Immunol Immunopathol 1994, 71:149-155.
26. Abraham E., Gyetko M.R., Kuhn K., Arcaroli J., Strassheim D., Park J.S., et al. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003, 170:5644-5651.
27. Bates E.E., Fridman W.H., Mueller C.G. The ADAMDEC1 (decysin) gene structure: evolution by duplication in a metalloprotease gene cluster on chromosome 8p12. Immunogenetics 2002, 54:96-105.
28. Crouser E.D., Culver D.A., Knox K.S., Julian M.W., Shao G., Abraham S., et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 2009, 179:929-938.
29. Mort J.S., Buttle D.J. Cathepsin B. Int J Biochem Cell Biol 1997, 29:715-720.
30. Steinfeld S., Maho A., Chaboteaux C., Daelemans P., Pochet R., Appelboom T., et al. Prolactin up-regulates cathepsin B and D expression in minor salivary glands of patients with Sjogren's syndrome. Lab Invest 2000, 80:1711-1720.
31. Mizuochi T., Yee S.T., Kasai M., Kakiuchi T., Muno D., Kominami E. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain. Immunol Lett 1994, 43:189-193.
32. Deiss L.P., Galinka H., Berissi H., Cohen O., Kimchi A. Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. EMBO J 1996, 15:3861-3870.
33. Perez P., Kwon Y.J., Alliende C., Leyton L., Aguilera S., Molina C., et al. Increased acinar damage of salivary glands of patients with Sjogren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios. Arthritis Rheum 2005, 52:2751-2760.
34. Zhou M., Zhang Y., Ardans J.A., Wahl L.M. Interferon-gamma differentially regulates monocyte matrix metalloproteinase-1 and -9 through tumor necrosis factor-alpha and caspase 8. J Biol Chem 2003, 278:45406-45413.
35. Wu A.J., Lafrenie R.M., Park C., Apinhasmit W., Chen Z.J., Birkedal-Hansen H., et al. Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line. J Cell Physiol 1997, 171:117-124.
36. Azuma M., Motegi K., Aota K., Hayashi Y., Sato M. Role of cytokines in the destruction of acinar structure in Sjogren's syndrome salivary glands. Lab Invest 1997, 77:269-280.
37. Iida J., Wilhelmson K.L., Ng J., Lee P., Morrison C., Tam E., et al. Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J 2007, 403:553-563.
38. Matute-Bello G., Wurfel M.M., Lee J.S., Park D.R., Frevert C.W., Madtes D.K., et al. Essential role of MMP-12 in Fas-induced lung fibrosis. Am J Respir Cell Mol Biol 2007, 37:210-221.
39. Poduval P., Sillat T., Virtanen I., Porola P., Konttinen Y.T. Abnormal basement membrane type IV collagen alpha-chain composition in labial salivary glands in Sjogren's syndrome. Arthritis Rheum 2009, 60:938-945.
40. Molina C., Alliende C., Aguilera S., Kwon Y.J., Leyton L., Martinez B., et al. Basal lamina disorganisation of the acini and ducts of labial salivary glands from patients with Sjogren's syndrome: association with mononuclear cell infiltration. Ann Rheum Dis 2006, 65:178-183.
41. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjögren's syndrome: what we know and what we should learn. J Autoimmun 2012, 39:4-8.
42. Gestermann N., Mekinian A., Comets E., Loiseau P., Puechal X., Hachulla E., et al. STAT4 is a confirmed genetic risk factor for Sjogren's syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun 2010, 11:432-438.
43. Sigurdsson S., Nordmark G., Garnier S., Grundberg E., Kwan T., Nilsson O., et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 2008, 17:2868-2876.
44. Kariuki S.N., Kirou K.A., MacDermott E.J., Barillas-Arias L., Crow M.K., Niewold T.B. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009, 182:34-38.
45. Mathur A.N., Chang H.C., Zisoulis D.G., Stritesky G.L., Yu Q., O'Malley J.T., et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 2007, 178:4901-4907.
46. Oke V., Wahren-Herlenius M. The immunobiology of Ro52(TRIM21) in autoimmunity: a critical review. J Autoimmun 2012, 39:77-82.
47. Myohanen H., Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 2004, 61:2840-2858.
48. Cuadrado E., Ortega L., Hernandez-Guillamon M., Penalba A., Fernandez-Cadenas I., Rosell A., et al. Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J Leukoc Biol 2008, 84:207-214.
49. Konttinen Y.T., Halinen S., Hanemaaijer R., Sorsa T., Hietanen J., Ceponis A., et al. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjogren's syndrome. Matrix Biol 1998, 17:335-347.
50. Azuma M., Aota K., Tamatani T., Motegi K., Yamashita T., Ashida Y., et al. Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjogren's syndrome patients. Arthritis Rheum 2002, 46:1585-1594.
51. Houghton A.M., Quintero P.A., Perkins D.L., Kobayashi D.K., Kelley D.G., Marconcini L.A., et al. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 2006, 116:753-759.
52. Reverter D., Maskos K., Tan F., Skidgel R.A., Bode W. Crystal structure of human carboxypeptidase M, a membrane-bound enzyme that regulates peptide hormone activity. J Mol Biol 2004, 338:257-269.
53. Deiteren K., Surpateanu G., Gilany K., Willemse J.L., Hendriks D.F., Augustyns K., et al. The role of the S1 binding site of carboxypeptidase M in substrate specificity and turn-over. Biochim Biophys Acta 2007, 1774:267-277.
54. Rehli M., Krause S.W., Andreesen R. The membrane-bound ectopeptidase CPM as a marker of macrophage maturation in vitro and in vivo. Adv Exp Med Biol 2000, 477:205-216.
55. Burger R., Zilow G. Complement-derived anaphylatoxins in natural immunity. The natural immune system: humoral factors 1993, 209. Oxford, New York. E. Sim (Ed.).
56. Levesque J.P., Winkler I.G. Mobilization of hematopoietic stem cells: state of the art. Curr Opin Organ Transplant 2008, 13:53-58.
57. Jalili A., Shirvaikar N., Marquez-Curtis L., Qiu Y., Korol C., Lee H., et al. Fifth complement cascade protein (C5) cleavage fragments disrupt the SDF-1/CXCR4 axis: further evidence that innate immunity orchestrates the mobilization of hematopoietic stem/progenitor cells. Exp Hematol 2010, 38:321-332.
58. DiScipio R.G., Schraufstatter I.U., Sikora L., Zuraw B.L., Sriramarao P. C5a mediates secretion and activation of matrix metalloproteinase 9 from human eosinophils and neutrophils. Int Immunopharmacol 2006, 6:1109-1118.
59. McQuibban G.A., Butler G.S., Gong J.H., Bendall L., Power C., Clark-Lewis I., et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001, 276:43503-43508.
60. Marquez-Curtis L., Jalili A., Deiteren K., Shirvaikar N., Lambeir A.M., Janowska-Wieczorek A. Carboxypeptidase M expressed by human bone marrow cells cleaves the C-terminal lysine of stromal cell-derived factor-1alpha: another player in hematopoietic stem/progenitor cell mobilization?. Stem Cell 2008, 26:1211-1220.
61. Barbolina M.V., Stack M.S. Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol 2008, 19:24-33.
62. Matias-Roman S., Galvez B.G., Genis L., Yanez-Mo M., de la Rosa G., Sanchez-Mateos P., et al. Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood 2005, 105:3956-3964.
63. Harris J., Schwinn N., Mahoney J.A., Lin H.H., Shaw M., Howard C.J., et al. A vitellogenic-like carboxypeptidase expressed by human macrophages is localized in endoplasmic reticulum and membrane ruffles. Int J Exp Pathol 2006, 87:29-39.
64. Hamilton G., Colbert J.D., Schuettelkopf A.W., Watts C. Cystatin F is a cathepsin C-directed protease inhibitor regulated by proteolysis. EMBO J 2008, 27:499-508.
65. Habib G.M., Shi Z.Z., Cuevas A.A., Lieberman M.W. Identification of two additional members of the membrane-bound dipeptidase family. FASEB J 2003, 17:1313-1315.
66. Oliveira L.J., McClellan S., Hansen P.J. Differentiation of the endometrial macrophage during pregnancy in the cow. PLoS One 2010, 5:e13213.
67. Katsiougiannis S., Kapsogeorgou E.K., Manoussakis M.N., Skopouli F.N. Salivary gland epithelial cells: a new source of the immunoregulatory hormone adiponectin. Arthritis Rheum 2006, 54:2295-2299.
68. Seror R., Bootsma H., Bowman S.J., Dörner T., Gottenberg J.E., Mariette X., et al. Outcome measures for primary Sjögren's syndrome. J Autoimmun 2012, 39:97-102.
69. Nakayamada S., Fujimoto T., Nonomura A., Saito K., Nakamura S., Tanaka Y. Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy. Rheumatology (Oxford) 2009, 48:1279-1282.